ImmuPharma (LON:IMM) Stock Price Up 34.1% - Still a Buy?

Key Points

• ImmuPharma's stock surged by 34.1%, reaching GBX 11.50 ($0.16) during trading, significantly above its previous close of GBX 8.06 ($0.11).
• The company has a market cap of £54.02 million and reported a negative PE ratio of -1,214.61, indicating ongoing financial challenges.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program targeting autoimmune diseases like Lupus through its novel treatment, Lupuzor™.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 34.1% during mid-day trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). Approximately 57,593,953 shares changed hands during trading, an increase of 656% from the average daily volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Up 34.1%

The company has a market cap of £54.02 million, a PE ratio of -1,214.61 and a beta of 1.53. The stock's 50 day simple moving average is GBX 2.38 and its two-hundred day simple moving average is GBX 2.70.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.